BioAtla, Inc. (BCAB)

NASDAQ: BCAB · IEX Real-Time Price · USD
2.30
-0.09 (-3.77%)
May 18, 2022 11:25 AM EDT - Market open
Market Cap86.05M
Revenue (ttm)250,000
Net Income (ttm)-100.96M
Shares Out37.41M
EPS (ttm)-2.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume148,368
Open2.30
Previous Close2.39
Day's Range2.27 - 2.34
52-Week Range2.01 - 51.83
Betan/a
AnalystsBuy
Price Target33.15 (+1,341.3%)
Earnings DateMay 4, 2022

About BCAB

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen...

IndustryBiotechnology
IPO DateDec 16, 2020
Employees56
Stock ExchangeNASDAQ
Ticker SymbolBCAB
Full Company Profile

Financial Performance

In 2021, BioAtla's revenue was $250,000, a decrease of -41.72% compared to the previous year's $429,000. Losses were -$95.40 million, 166.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price forecast is 33.15, which is an increase of 1,341.30% from the latest price.

Price Target
$33.15
(1,341.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –

1 week ago - GlobeNewsWire

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and o...

1 month ago - GlobeNewsWire

BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

SAN DIEGO, March 1, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...

2 months ago - PRNewsWire

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftam...

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...

Other symbols:BMY
4 months ago - PRNewsWire

BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today annou...

4 months ago - PRNewsWire

BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...

6 months ago - PRNewsWire

BioAtla Announces Private Placement of 2.7 Million Shares

SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeut...

7 months ago - PRNewsWire

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update

SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...

9 months ago - PRNewsWire

BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update

SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutic...

1 year ago - PRNewsWire

BioAtla to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announ...

1 year ago - PRNewsWire

Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

1 year ago - Benzinga

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additi...

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...

1 year ago - PRNewsWire

BioAtla Announces Pricing of Initial Public Offering

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...

1 year ago - PRNewsWire